Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.ORCID iD: 0000-0003-0663-2220
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Umeå University, Faculty of Medicine, Department of Pharmacology and Clinical Neuroscience, Clinical Neuroscience.
Show others and affiliations
2015 (English)In: Neurology: Neuroimmunology & Neuroinflammation, E-ISSN 2332-7812, Vol. 2, no 2, article id e79Article in journal (Refereed) Published
Abstract [en]

Objective: We are conducting an open-label phase 1b study on the efficacy of intrathecal (IT) administration of rituximab, provided via an Ommaya reservoir, for the treatment of progressive multiple sclerosis (PMS). The objective of this initial study was to monitor B lymphocytes in peripheral blood (PB) and CSF from the first 10 patients 1 year posttreatment.

Methods: Dose titration was performed with daily escalation from 1 mg to 25 mg IT rituximab (n=3). Lymphocyte subpopulations were monitored daily during dose escalation in PB by flow cytometry and subsequently every 3 months for 1 year, after a total dose of 3 x 25 mg. PB B-lymphocyte subpopulations for the remaining patients (n = 7) were monitored at regular intervals. CSF lymphocyte subpopulations for all patients were monitored by flow cytometry every 2-3 months.

Results: The PB B-lymphocyte count dropped rapidly after the first 2 injections (total dose of 3.5 mg IT rituximab) to undetectable levels. Three 25-mg doses given once per week depleted peripheral B lymphocytes entirely for the following 3-6 month period.

Conclusions: Monoclonal antibodies seem to rapidly redistribute to the peripheral compartment following IT injection. Ultra-low doses of rituximab given IT are sufficient to cause complete depletion of peripheral B lymphocytes, indicating that low-dose IT treatment has the potential to be effective in both the CNS and systemic compartments.

Classification of evidence: This study provides Class IV evidence that for patients with PMS, rituximab provided via an Ommaya reservoir depletes peripheral blood B lymphocytes.

Place, publisher, year, edition, pages
Lippincott Williams & Wilkins, 2015. Vol. 2, no 2, article id e79
National Category
Neurology
Identifiers
URN: urn:nbn:se:umu:diva-142801DOI: 10.1212/NXI.0000000000000079ISI: 000218611600003PubMedID: 25745637Scopus ID: 2-s2.0-84949575977OAI: oai:DiVA.org:umu-142801DiVA, id: diva2:1168317
Available from: 2017-12-20 Created: 2017-12-20 Last updated: 2023-09-07Bibliographically approved
In thesis
1. Studies of the Biology of Intrathecal Treatment in Progressive MS
Open this publication in new window or tab >>Studies of the Biology of Intrathecal Treatment in Progressive MS
2020 (English)Doctoral thesis, comprehensive summary (Other academic)
Alternative title[sv]
Studier av biologin vid intratekal behandling vid progressiv MS
Abstract [en]

Background: Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease, affecting the central nervous system (CNS). About 85% of afflicted present with a relapsing-remitting form of the disease (RRMS), for which a breakthrough in treatment was made in 2008 with rituximab, an antibody directed towards CD20, a surface antigen on B-cells. These findings also contributed to cementing the importance of the B-cell’s role in MS pathophysiology. However, MS also exist as a progressive phenotype, affecting most MS patients either from onset or after a transition from RRMS, and for progressive MS the same treatment effect of anti-CD20 has not been observed. Still, studies have found follicle-like structures containing B-cells in meninges and subarachnoid space of the cortex in progressive MS brains, supporting the involvement of B-cells. Evidence also support the existence of a chronic, low-grade inflammatory process compartmentalised within the CNS that correlates with the progressive phase of MS, which may present a treatment barrier towards anti-CD20. Peripherally administrated therapeutic antibodies cross the intact blood-brain barrier with low efficiency with only 0.1-0.5% of the plasma concentration occurring in the cerebrospinal fluid (CSF). Intrathecal (IT) administration circumvents the blood-brain barrier, presenting an opportunity to better target the CNS B-cells.

Aims: To evaluate the safety and feasibility of intrathecal anti-CD20 therapy with rituximab in progressive MS, its effect on disease progression through clinical parameters, and impact on biomarkers in CSF. Furthermore, this thesis aimed to evaluate the effect on biomarkers representative of cell injury related to insertion of a ventricular catheter for drug administration and to examine the interstitial milieu in the brain through microdialysis (MD).

Methods: The thesis is based on the open-label, phase IIb, multicentre clinical trial Intrathecal Treatment Trial in Progressive Multiple Sclerosis (ITT-PMS; EudraCT 2008-002626-11), in which 23 participants received IT treatment with rituximab, and the extended follow-up study, ITT-PMS extension (EudraCT 2012-000721-53). All participants received a ventricular catheter and an Ommaya reservoir for drug administration through a neurosurgical procedure, and 10 participants received a MD catheter in parallel to the ventricular catheter for 10 days. The treatment effect was evaluated by regular clinical evaluations and analyses of CSF. The clinical outcome was evaluated through walking and upper-limb function tests, and by clinical evaluation scales. Levels of selected CSF biomarkers were analysed from the same time-points as the clinical evaluations.

Results: After the completion of the extension trial, one clinical parameter (cognitive performance) showed improvement but could most likely be explained by a learning effect. Worsening of walking speed was observed, while the remaining clinical parameters showed no change. Two severe adverse events occurred in the form of low-virulent bacterial meningitis caused by Propionibacterium, but both were treated effectively with antibiotics without residual symptoms. A ‘spike’ was noticed in the level of lumbar CSF neurofilament light (NFL) following surgery but returned to pre-surgery baseline within 6-12 months. No change was observed for any of the other lumbar CSF biomarkers. No meaningful correlation of protein levels was observed when comparing MD samples, ventricular CSF, and lumbar CSF.

Conclusions: Intrathecal treatment through intraventricular administration was well tolerated but not without risks. A continued progression was observed in gait impairment. The insertion of the ventricular catheter caused white matter injury, measured through an increase in NFL in lumbar CSF, in direct association with the surgical procedure. No impact was observed on other CSF biomarkers. There was a poor correlation between different CNS compartments regarding protein levels, arguing for caution in drawing conclusions about brain pathophysiology from lumbar CSF samples.

Place, publisher, year, edition, pages
Umeå: Umeå University, 2020. p. 68
Series
Umeå University medical dissertations, ISSN 0346-6612 ; 2082
Keywords
Progressive Multiple Sclerosis, intrathecal treatment, Ommaya reservoir, anti-CD20 therapy, microdialysis, cerebrospinal fluid, CNS compartments, Progressiv Multipel Skleros, intratekal behandling, Ommaya reservoar, anti-CD20 terapi, mikrodialys, ryggmärgsvätska, sektioner i centrala nervsystemet
National Category
Neurology
Research subject
Neurology
Identifiers
urn:nbn:se:umu:diva-169322 (URN)978-91-7855-232-0 (ISBN)978-91-7855-233-7 (ISBN)
Public defence
2020-04-24, DBS-enhetens bibliotek, NUS, Norrlands Universitetssjukhus, Umeå, 09:00 (Swedish)
Opponent
Supervisors
Note

Ny lokal: På spikbladet anges tidigare fastslagna lokal. 

Available from: 2020-04-03 Created: 2020-03-31 Last updated: 2021-02-10Bibliographically approved

Open Access in DiVA

fulltext(512 kB)410 downloads
File information
File name FULLTEXT01.pdfFile size 512 kBChecksum SHA-512
edb871eacdc7e9f3806cf36e78264e846228a37542ec253c019c4e03f01268e1746c3a3e4ff409bbf5bfb15cdabd94670c1503107e8b9b897635cdd444f96d2c
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Svenningsson, AndersBergman, JoakimDring, AnnVågberg, MattiasBirgander, RichardGilthorpe, JonathanBergenheim, Tommy

Search in DiVA

By author/editor
Svenningsson, AndersBergman, JoakimDring, AnnVågberg, MattiasBirgander, RichardGilthorpe, JonathanBergenheim, Tommy
By organisation
Clinical NeuroscienceDiagnostic Radiology
In the same journal
Neurology: Neuroimmunology & Neuroinflammation
Neurology

Search outside of DiVA

GoogleGoogle Scholar
Total: 412 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 809 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf